These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15161707)

  • 1. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment.
    Raspollini MR; Amunni G; Villanucci A; Pinzani P; Simi L; Paglierani M; Taddei GL
    Clin Cancer Res; 2004 May; 10(10):3500-3. PubMed ID: 15161707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT.
    Raspollini MR; Pinzani P; Simi L; Amunni G; Villanucci A; Paglierani M; Taddei GL
    Gynecol Oncol; 2005 Aug; 98(2):334-5. PubMed ID: 16039311
    [No Abstract]   [Full Text] [Related]  

  • 4. C-kit expression in uterine leiomyosarcomas: an immunocytochemical study of 29 cases of malignant smooth muscle tumors of the uterus.
    Raspollini MR; Villanucci A; Amunni G; Paglierani M; Taddei A; Taddei GL
    J Chemother; 2003 Feb; 15(1):81-4. PubMed ID: 12678420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
    Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
    Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The protooncogene c-KIT is expressed in leiomyosarcomas of the uterus.
    Raspollini MR; Paglierani M; Taddei GL; Villanucci A; Amunni G; Taddei A
    Gynecol Oncol; 2004 Jun; 93(3):718. PubMed ID: 15196872
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
    J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib is not a potential alternative treatment for uterine leiomyosarcoma.
    Serrano C; Mackintosh C; Herrero D; Martins AS; de Alava E; Hernández T; Pérez-Fontán J; Abad M; Pérez A; Serrano E; Bullón A; Orfao A
    Clin Cancer Res; 2005 Jul; 11(13):4977-9; author reply 4979-80. PubMed ID: 16000598
    [No Abstract]   [Full Text] [Related]  

  • 11. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
    Adams SF; Hickson JA; Hutto JY; Montag AG; Lengyel E; Yamada SD
    Gynecol Oncol; 2007 Mar; 104(3):524-8. PubMed ID: 17049587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
    Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
    J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
    Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of bcl-2 and bax protein in uterine leiomyosarcomas and leiomyomas].
    Zhang ZL; Zhang Y; Zhou JH
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 30(2):183-6. PubMed ID: 15898430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
    Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of KIT expression in human tumors.
    Went PT; Dirnhofer S; Bundi M; Mirlacher M; Schraml P; Mangialaio S; Dimitrijevic S; Kononen J; Lugli A; Simon R; Sauter G
    J Clin Oncol; 2004 Nov; 22(22):4514-22. PubMed ID: 15542802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.
    Wang L; Felix JC; Lee JL; Tan PY; Tourgeman DE; O'Meara AT; Amezcua CA
    Gynecol Oncol; 2003 Aug; 90(2):402-6. PubMed ID: 12893208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
    Geller MA; Argenta P; Bradley W; Dusenbery KE; Brooker D; Downs LS; Judson PL; Carson LF; Boente MP
    Gynecol Oncol; 2004 Dec; 95(3):632-6. PubMed ID: 15581975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.